Category
- Alcohol Deterrents Clinical Trials
- Analgesics, Narcotic Clinical Trials
- Analgesics, Non-narcotic Clinical Trials
- Anti-allergic Agents Clinical Trials
- Anti-arrhythmia Agents Clinical Trials
- Anti-dyskinesia Agents Clinical Trials
- Anti-infective Agents Clinical Trials
- Anti-inflammatory Agents Clinical Trials
- Anti-obesity Agents Clinical Trials
- Anticoagulants Clinical Trials
- Anticonvulsants Clinical Trials
- Antiemetics Clinical Trials
- Antihypertensive Agents Clinical Trials
- Antilipemic Agents Clinical Trials
- Antineoplastic Agents Clinical Trials
- Antisickling Agents Clinical Trials
- Antitussive Agents Clinical Trials
- Blood Substitutes Clinical Trials
- Bone Density Conservation Agents Clinical Trials
- Cardiotonic Agents Clinical Trials
- Central Nervous System Stimulants Clinical Trials
- Channel Blockers Clinical Trials
- Coagulants Clinical Trials
- Dermatologic Agents Clinical Trials
- Fibrinolytic Agents Clinical Trials
- Gastrointestinal Agents Clinical Trials
- Hematinics Clinical Trials
- Hypnotics And Sedatives Clinical Trials
- Hypoglycemic Agents Clinical Trials
- Micronutrients Clinical Trials
- Muscle Relaxants, Central Clinical Trials
- Narcotic Antagonists Clinical Trials
- Natriuretic Agents Clinical Trials
- Neuroprotective Agents Clinical Trials
- Nitric Oxide Donors Clinical Trials
- Nootropic Agents Clinical Trials
- Ntral Nervous System Depressants Clinical Trials
- Platelet Aggregation Inhibitors Clinical Trials
- Psychotropic Drugs Clinical Trials
- Renal Agents Clinical Trials
- Reproductive Control Agents Clinical Trials
- Respiratory System Agents Clinical Trials
- Rheumatic Agents Clinical Trials
- Vasoconstrictor Agents Clinical Trials
- Vasodilator Agents Clinical Trials
Inosine pranobex Clinical Trials
Listings Sponsored By:
To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): - Comparison of total helper and suppressor T-cell numbers among the groups. - Comparison of changes [more...] in natural killer cell activity. - Comparison of other laboratory findings among the groups. Clinical changes: - Comparison of the frequency of opportunistic infections among the groups. - Comparison of the frequency of the development of AIDS-related malignancies. - Comparison of other clinical manifestations relative to severity and time of onset.
Status: Completed Start Date: Completion Date:
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of [more...] the 28 days of treatment), measured by one or more of the following immunological parameters: - Increase in natural killer (NK) cell activity. - Increase in total T-cells (OKT-11). - Increases in absolute number and percentage of T-helper cells (OKT-4).
Status: Completed Start Date: Completion Date:
The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include: Signs and symptoms: - Lymphadenopathy. [more...] - Fever. - Weight loss. - Occurrence of opportunistic infections. Cell-mediated immune system parameters: - T-helper cell (OKT4) numbers and proportions. - T-suppressor cell (OKT8) numbers and proportions. - Natural killer (NK) cell activity. - Lymphocyte blastogenic response to phytohemagglutinin (PHA). - Lymphocyte blastogenic response to pokeweed mitogen (PWM). - Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile. - Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora. Safety parameters: - Blood chemistry including serum uric acid (PurposeA-12). - Complete blood count (CBC). - Platelet count.
Status: Completed Start Date: Completion Date:
To determine the safety and effectiveness of treatment with ribavirin (RBV) plus isoprinosine (INPX) in preventing the development of AIDS in patients infected with the AIDS virus (HIV). Also to determine the maximal dose of RBV that can be tolerated by [more...] HIV-infected patients when RBV is given with INPX. The patients may or may not have generalized lymphadenopathy syndrome (LAS). RBV has prevented the development of AIDS in some HIV-infected patients with LAS and INPX has stimulated the immune system of patients infected with HIV. The immune system fights infections in the human body, and the HIV attacks T cells that are an important part of the immune system. Reports from individual cases treated with both RBV and INPX suggest that clinical improvements occurred in HIV-infected patients, but there is no reliable information on the safety and effectiveness of this drug combination in such patients.
Status: Completed Start Date: Completion Date:
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: - Comparison of total helper and suppressor T-cell [more...] number between the groups. - Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups. - Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.
Status: Completed Start Date: Completion Date:
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser [more...] opportunistic infections and/or other conditions associated with ARC.
Status: Completed Start Date: Completion Date:
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of [more...] the 28 days of treatment), measured by one or more of the following immunologic parameters: - Increase in natural killer (NK) cell activity. - Increase in total T-cells (OKT-11). - Increases in absolute number and percentages of T-helper cells (OKT-4).
Status: Completed Start Date: Completion Date:
Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.
Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.
Inosine pranobex Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Inosine pranobex. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Inosine pranobex studies are federally regulated with strict guidelines to protect patients.
Trials News
03/14/2010
There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.
03/07/2010
There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.
02/28/2010
Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.